Omkar Pharmachem

Which are the latest news on Omkar Pharmachem?

Why is Omkar Pharmachem Ltd falling/rising?

As of 05-Sep, Omkar Pharmachem Ltd's stock price is at Rs. 9.26, down 4.93% and hitting a new 52-week low. The stock has declined 15.97% over the past week and 47.33% over the past month, indicating a persistent bearish trend despite increased investor participation.

As of 05-Sep, Omkar Pharmachem Ltd's stock price is falling, currently at Rs. 9.26, which represents a decrease of Rs. 0.48 or 4.93%. The stock has hit a new 52-week low today and has been on a downward trend, having fallen consecutively for the last two days, resulting in a total decline of 9.66% during this period. Over the past week, the stock has underperformed significantly, with a decline of 15.97%, compared to a minor drop of 0.97% in the benchmark Sensex. Additionally, the stock has shown a substantial decline of 47.33% over the past month, while the Sensex has only decreased by 2.44%. <BR><BR>Omkar Pharmachem is also trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a persistent bearish trend. Despite a notable increase in investor participation, with delivery volume rising by 586.94% against the 5-day average, the overall performance remains weak, as the stock has underperformed its sector by 4.48% today. These factors collectively contribute to the ongoing decline in the stock price of Omkar Pharmachem Ltd.

Who are in the management team of Omkar Pharmachem?

The management team of Omkar Pharmachem includes Anurag Sharma (Managing Director), Parminder Sharma (Non Executive Director), Mamta Pachori (Non Executive Independent Director), Janak Raj (Non Executive Independent Director), and Pankaj Singh (Company Secretary & Compliance Officer).

The management team of Omkar Pharmachem includes the following individuals:<BR><BR>1. Anurag Sharma - Managing Director<BR>2. Parminder Sharma - Non Executive Director<BR>3. Mamta Pachori - Non Executive Independent Director<BR>4. Janak Raj - Non Executive Independent Director<BR>5. Pankaj Singh - Company Secretary & Compliance Officer<BR><BR>If you have any more questions about the company or its operations, feel free to ask!

What does Omkar Pharmachem do?

Omkar Pharmachem Ltd is a micro-cap company focused on pharmaceuticals and chemical products, with no recent sales or profits reported. It was incorporated in 1995 and currently provides support services in its industry.

Overview:<BR>Omkar Pharmachem Ltd is engaged in the business of pharmaceuticals and chemical products within the commodity chemicals industry, categorized as a micro-cap company.<BR><BR>History:<BR>The company was incorporated on March 31, 1995. It has not conducted any commercial activity during the year and is currently focused on providing support services related to pharmaceuticals and chemicals. The latest quarterly results reported are for June 2026, showing no sales or profit.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 11 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 117.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.01 <BR>Return on Equity: 0.25% <BR>Price to Book: 0.30 <BR><BR>Contact Details:<BR>Address: 501 Mahakant Bldg Ashram Road, Opp V S Hospital Ellisbridge Ahmedabad Gujarat : 380006 <BR>Tel: 91-079-26580892 <BR>Email: investors.opl@gmail.com <BR>Website: http://www.omkarpharmachem.co.in

Who are the peers of the Omkar Pharmachem?

Omkar Pharmachem's peers include Square Four Pro., Tulasee Bio-Eth., Emmessar Biotech, Kobo Biotech, and others. Kobo Biotech has the highest 1-year return at 134.04%, while Square Four Pro. has the lowest at -11.10%.

Peers: The peers of Omkar Pharmachem are Square Four Pro., Tulasee Bio-Eth., Emmessar Biotech, Kobo Biotech, Link Pharma Chem, Sreechem Resins, Kuwer Industries, Lime Chemicals, Bhagawati Oxygen, and Padmanabh Inds.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sreechem Resins, while Average management risk is found at Emmessar Biotech and Kuwer Industries, and the rest have Below Average or do not qualify. Below Average growth is noted at Emmessar Biotech, Link Pharma Chem, Kuwer Industries, Lime Chemicals, and the rest do not qualify. Capital Structure ratings show Below Average at Emmessar Biotech, Link Pharma Chem, Kuwer Industries, Lime Chemicals, and the rest do not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Kobo Biotech at 134.04%, while the lowest is Square Four Pro. at -11.10%, and Omkar Pharmachem's 1-year return is not available for comparison. Additionally, Sreechem Resins, Kuwer Industries, Lime Chemicals, and Padmanabh Inds. have negative six-month returns.

How big is Omkar Pharmachem?

As of 31st August, Omkar Pharmachem Ltd has a market capitalization of 11.00 Cr, with recent net sales of 0.00 Cr and a net profit of 0.09 Cr. Shareholder's funds are 9.43 Cr and total assets amount to 9.57 Cr as of March 2025.

As of 31st August, Omkar Pharmachem Ltd has a market capitalization of 11.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Omkar Pharmachem reported Net Sales of 0.00 Cr and a Net Profit of 0.09 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 9.43 Cr and Total Assets of 9.57 Cr.

When is the next results date for Omkar Pharmachem Ltd?

The next results date for Omkar Pharmachem Ltd is 13 August 2026.

The next results date for Omkar Pharmachem Ltd is scheduled for 13 August 2026.

Is Omkar Pharmachem overvalued or undervalued?

As of August 12, 2025, Omkar Pharmachem is considered very expensive and overvalued, with a PE ratio of 25.90 and a PEG ratio of 4.92, indicating its growth prospects do not justify its current price despite a strong historical return of 323.06%.

As of 12 August 2025, the valuation grade for Omkar Pharmachem has moved from risky to very expensive, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios include a PE ratio of 25.90, an EV to EBIT ratio of 26.13, and a ROCE of only 3.17%, which raises concerns about its profitability relative to its valuation.<BR><BR>In comparison to its peers, Omkar Pharmachem's valuation metrics appear less favorable. For instance, Sun Pharma has a PE ratio of 33.93, while Cipla offers a more attractive PE of 22.77. Additionally, the PEG ratio of 4.92 suggests that the company's growth prospects may not justify its current price. Despite a strong historical performance over the last decade, with a return of 323.06%, the current valuation does not align with its financial fundamentals, reinforcing the conclusion that Omkar Pharmachem is overvalued.

How has been the historical performance of Omkar Pharmachem?

Omkar Pharmachem has shown minimal financial activity, with net sales at zero since Mar'18, but has stabilized other operating income at 0.54 Cr since Mar'22. While profit metrics have gradually improved, the company still carries negative reserves, though the deficit has decreased from -1.42 Cr in Mar'21 to -0.65 Cr in Mar'25.

Answer:<BR>The historical performance of Omkar Pharmachem shows a consistent trend of minimal financial activity over the years, with net sales remaining at zero from Mar'18 to Mar'25. The company has reported other operating income of 0.54 Cr for Mar'24 and Mar'25, which is an increase from 0.27 Cr in Mar'21. Total operating income has remained stable at 0.54 Cr since Mar'22. The total expenditure, excluding depreciation, has varied slightly, with a peak of 0.27 Cr in Mar'22 and a low of 0.23 Cr in Mar'23, leading to an operating profit (PBDIT) that has fluctuated around 0.29 Cr to 0.31 Cr in recent years. Profit before tax has shown a gradual improvement, reaching 0.27 Cr in Mar'25, while profit after tax has also increased slightly to 0.20 Cr in the same period. The company has maintained a negative reserve balance, which has improved from -1.42 Cr in Mar'21 to -0.65 Cr in Mar'25. <BR><BR>Breakdown:<BR>Omkar Pharmachem's financial performance indicates a lack of significant revenue generation, with net sales consistently reported as zero over the past several years. The company has, however, managed to generate some other operating income, which has stabilized at 0.54 Cr since Mar'22, reflecting a modest increase from previous years. Total expenditure has remained relatively low, allowing for a positive operating profit that has hovered around 0.29 Cr to 0.31 Cr in the last few years. Profit before tax has shown a positive trend, reaching 0.27 Cr in Mar'25, while profit after tax has also seen slight growth, indicating some operational stability. Despite these improvements, the company continues to carry negative reserves, although there has been a gradual reduction in the deficit over the years, suggesting a potential for future recovery. Overall, the financial data reflects a company that has not yet achieved significant operational success but is showing signs of gradual improvement in profitability metrics.

What is the technical trend for Omkar Pharmachem?

As of May 12, 2025, Omkar Pharmachem shows a mildly bullish trend, supported by daily moving averages and Bollinger Bands, though caution is advised due to bearish signals from the weekly and monthly MACD and RSI.

As of 12 May 2025, the technical trend for Omkar Pharmachem has changed from does not qualify to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly and monthly MACD and RSI readings are mildly bearish. However, the Bollinger Bands are showing a mildly bullish trend on both weekly and monthly time frames. The KST is bullish on both weekly and monthly, which adds some strength to the mildly bullish outlook. Overall, the current stance is mildly bullish, but caution is advised due to the bearish signals from the MACD and RSI on the weekly and monthly charts.

Who are the top shareholders of the Omkar Pharmachem?

The top shareholders of Omkar Pharmachem include promoter Shah Kirtikumar Laxmichand with 0.02% and public shareholder Kuldeep Singh with 3.72%. Individual investors hold a significant 98.36% of the shares, with no pledged promoter holdings or investments from mutual funds or foreign institutional investors.

The top shareholders of Omkar Pharmachem include Shah Kirtikumar Laxmichand, who is the promoter with the highest holding at 0.02%. The highest public shareholder is Kuldeep Singh, holding 3.72%. Additionally, individual investors collectively hold a significant portion, accounting for 98.36% of the shares. Notably, there are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares.

Has Omkar Pharmachem declared dividend?

No Dividend History Available